GM Salmon Goes Commercial

Environment Canada allows production of genetically modified salmon eggs at commercial levels.

Written byAbby Olena, PhD
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Young Atlantic salmon FLICKR, U.S. FISH AND WILDLIFE SERVICEAs controversy swirls over genetic engineering of foods, a genetically modified (GM) animal is one step closer to becoming a main course. AquaBounty Technologies, the firm that makes genetically modified salmon that grow twice as fast as non-GM salmon, has been given permission by Environment Canada to produce its GM fish eggs on a commercial scale in its Prince Edward Island research facility, according to a press release.

The GM salmon, called AquAdvantage, are Atlantic salmon (Salmo salar) with an extra gene from Chinook salmon (Oncorhynchus tshawytscha) engineered into their genomes. The terms of the decision attempted to carefully control the GM eggs, which are all-female and sterile, according to the press release. “There are strict measures in place to prevent the release of this fish into the food chain,” an Environment Canada spokesman wrote in an e-mail to The Guardian.

GM salmon is still not approved for human consumption in Canada. “It’s only the status of the facility moving from research and development to essentially a facility that could be used for commercial purposes,” AquaBounty CEO Ron Stotish told The Canadian Press. “We would be regulated as a novel food in Canada ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies